Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with ...

On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...

There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Check the time stamp on this data. Updated AI-Generated Signals for Viking Therapeutics Inc. (VKTX) available here: VKTX.

Did Viking Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VKTX ...

The stock VKTX, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech that rose in prominence this year. The drugmaker's shares ...